Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | PYGB | P11216 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.40 |
| ▸ | HEXA | P06865 | 1/20 | 0.40 |
| ▸ | HEXB | P07686 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899709 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL17035726 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12899816 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL10201254 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL23844307 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL22174657 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL25090768 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21621598 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL20805367 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21146567 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4810784-A | 2-AMINO-2-DEOXYGLYCOPYRANOSYL UNIT TO SUBSTANCE HAVING AMINO GROUP | ADVANCED MEDICAL OPTICS, INC. | 1989-03-07 | — | — | US | claimed |
| US-4613665-A | HEPARIN, MUCOPOLYSACCHARIDES COUPLED TO GELS, PLASTICS, PROTEINS | LARM OLLE (SE) | 1986-09-23 | — | — | US | claimed |
| EP-0086186-B1 | A PROCESS FOR COVALENT COUPLING FOR THE PRODUCTION OF CONJUGATES, AND PRODUCTS HEREBY OBTAINED | Larm, Olle (SE) | 1986-05-21 | — | — | EP | claimed |
| WO-2023235464-A1 | NOVEL EQUILIBRATIVE NUCLEOSIDE TRANSPORTER INHIBITORS AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201207-A1 | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20210214607-A1 | LONG WAVELENGTH EMITTING CHEMILUMINESCENT PROBES | NEMIS TECHNOLOGIES AG (CH) | 2021-07-15 | — | — | US | disclosed |
| WO-2020233706-A1 | DRUG FOR TREATING MANIC MENTAL DISORDER AND SCHIZOPHRENIA | 华东理工大学 (CN) | 2020-11-26 | — | — | WO | disclosed |
| EP-3512486-B1 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2020-10-21 | — | — | EP | disclosed |
| US-5391580-A | Polymer layer directly attached to polypropylene tube and active heparin linked through covalent bond to the layer | ANATRACE INC. (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0313538-A2 | Monoclonal antibody, a process for its preparation and the use thereof | CARMEDA AB (SE) | 1989-04-26 | — | — | EP | disclosed |
| US-4810784-A | 2-AMINO-2-DEOXYGLYCOPYRANOSYL UNIT TO SUBSTANCE HAVING AMINO GROUP | ADVANCED MEDICAL OPTICS, INC. | 1989-03-07 | — | — | US | disclosed |
| US-4810784-A | 2-AMINO-2-DEOXYGLYCOPYRANOSYL UNIT TO SUBSTANCE HAVING AMINO GROUP | ADVANCED MEDICAL OPTICS, INC. | 1989-03-07 | — | — | US | disclosed |
| US-4613665-A | HEPARIN, MUCOPOLYSACCHARIDES COUPLED TO GELS, PLASTICS, PROTEINS | LARM OLLE (SE) | 1986-09-23 | — | — | US | disclosed |
| US-4613665-A | HEPARIN, MUCOPOLYSACCHARIDES COUPLED TO GELS, PLASTICS, PROTEINS | LARM OLLE (SE) | 1986-09-23 | — | — | US | disclosed |
| EP-0086186-B1 | A PROCESS FOR COVALENT COUPLING FOR THE PRODUCTION OF CONJUGATES, AND PRODUCTS HEREBY OBTAINED | Larm, Olle (SE) | 1986-05-21 | — | — | EP | disclosed |
| EP-0086186-A1 | A process for covalent coupling for the production of conjugates, and products hereby obtained | Larm, Olle (SE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0086186-A1 | A process for covalent coupling for the production of conjugates, and products hereby obtained | Larm, Olle (SE) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | LGALS1 2210/4885LGALS3 2468/4885LGALS9 1190/4885 |
| US-20210214607-A1 | LONG WAVELENGTH EMITTING CHEMILUMINESCENT PROBES | VEGFA, GUSB, NR2E3 | LGALS1 502/4885LGALS3 469/4885LGALS9 979/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | LGALS1 2210/4885LGALS3 2468/4885LGALS9 1190/4885 |
| US-20230201207-A1 | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | NME2, NTPCR, TYMP | LGALS1 1545/4885LGALS3 2052/4885LGALS9 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.